Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults

Journal of Psychiatric Research

Volumn 43, Issue 6, 2009, Pages 664-670

  Greenberg, William M ^a,b   Benedict, Melissa M ^b   Doerfer, Joanna ^b   Perrin, Megan ^b   Panek, Laura ^b   Cleveland, W Louis ^c   Javitt, Daniel C ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Glutamate; Glycine; NMDA receptor; Obsessive compulsive disorder; Randomized controlled trial; Treatment

Indexed keywords

GLYCINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHIATRIST; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 60949090429     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2008.10.007     Document Type: Article

References (50)

1. Anand A., Charney D.S., Oren D.A., Berman R.M., Hu X.S., Cappiello A., et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Archives of General Psychiatry 57 (2000) 270-276
2. Aracava Y., Pereira E.F.R., Maelicke A., and Albuquerque E.X. Memantine blocks (α7* nicotinic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons. The Journal of Pharmacology and Experimental Therapeutics 312 (2005) 1195-1205
3. Arnold P.D., Rosenberg D.R., Mundo E., Tharmalingam S., Kennedy J.L., and Richter M.A. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology 174 (2004) 530-538
4. Arnold P.D., Sicard T., Burroughs E., Richter M.A., and Kennedy J.L. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Archives of General Psychiatry 63 (2006) 769-776
5. Baker D.A., Madayag A., Kristiansen L.V., Meador-Woodruff J.H., Haroutunian V., and Raju I. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology 33 (2008) 1760-1762
6. Baxter Jr. L.R., Schwartz J.M., Bergman K.S., Szuba M.P., Guze B.H., Mazziotta J.C., Alazraki A., Selin C.E., Ferng HK., Munford P., and Phelps M.E. Caudate glucose metabolic rate change with both drug and behavior therapy for OCD. Archives of General Psychiatry 49 (1992) 681-689
7. Buisson B., and Bertrand D. Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor. Molecular Pharmacology 53 (1998) 555-563
8. Carlsson M.L. On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatrica Scandinavica 102 (2000) 401-413
9. Chakrabarty K., Bhattacharyya S., Christopher R., and Khanna S. Glutamergic dysfunction in OCD. Neuropsychopharmacology 30 (2005) 1735-1740
10. Cleveland WL, DeLaPaz RL, Fawwaz RA, Challop RS. Effective treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder with high-dose glycine in a 5-year period., submitted for publication.
11. Coric V., Milanovic S., Wasylink S., Patel P., Malison R., and Krystal J.H. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology 167 (2003) 219-220
12. Coric V., Taskiran S., Pittenger C., Wasylink S., Mathalon D.H., Valentine G., Saksa J., Wu Yt., Gueorguieva R., Sanacora G., Malison R.T., and Krystal J.H. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biological Psychiatry 58 (2005) 424-428
13. Cummings J.L. Anatomic and behavioral aspects of frontal-subcortical circuits. Annals of the New York Academy of Sciences 769 (1995) 1-13
14. Dickel D.E., Veenstra-VanderWeele J., Cox N.J., Wu X., Fischer D.J., Van Etten-Lee M., Himle J.A., Leventhal B.L., Cook Jr. E.H., and Hanna G.L. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Archives of General Psychiatry 63 (2006) 778-785
15. Egashira, N., Okuno, R. Harada, S., Matsushita, M., Mishima, K., Iwasaki, K., Nishimura, R., Oishi, R., Fujiwara, M., 2008. Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. European Journal of Pharmacology. doi:10.1016/j.ejphar.2008.01.035.
16. Giustizieri M., Cucchiaroni M.L., Guatteo E., Bernardi G., Mercuri N.B., and Berretta N. Memantine inhibits ATP-dependent K+ conductances in dopamine neurons of the rat substantia nigra pars compacta. Journal of Pharmacology and Experimental Therapeutics 322 (2007) 721-729
17. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., Heninger G.R., and Charney D.S. The yale-brown obsessive compulsive scale. I: development, use and reliability. Archives of General Psychiatry 46 (1989) 1006-1011
18. Grant P., Lougee L., Hirschtritt M., and Swedo S.E. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology 17 (2007) 761-767
19. Heinrichs D.W., Hanlon T.E., and Carpenter Jr. W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10 (1984) 388-397
20. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., and Lichenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry 56 (1999) 29-36
21. Heresco-Levy U., Ermilov M., Lichtenberg P., Bar G., and Javitt D.C. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biological Psychiatry 55 (2004) 165-171
22. Javitt D.C., Silipo G., Cienfuegos A., Shelley A.M., Bark N., Park M., Lindenmayer J.P., Suckow R., and Zukin S.R. Adjunctive high-dose glycine in the treatment of schizophrenia. International Journal of Neuropsychopharmacologyogy 4 (2001) 385-391
23. Javitt D.C., Balla A., Burch S., Suckow R., Xie S., and Sershen H. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 29 (2004) 300-307
24. Javitt D.C. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Current Opinion in Psychiatry 19 (2006) 151-157
25. Jenike M.A. Obsessive-compulsive disorder. New England Journal of Medicine 350 (2004) 259-265
26. Karno M., Golding J.M., Sorenson S.B., and Burnam A. The epidemiology of obsessive-compulsive disorder in five US communities. Archives of General Psychiatry 45 (1988) 1094-1099
27. Kemp D.E., Gilmer W.S., Fleck J., and Dago P.L. An association of intrusive, repetitive phrases with lamotrigine treatment in bipolar II disorder. CNS Spectrums 12 (2007) 106-111
28. Kowalchuk R.K., Keselman H.J., Algina J., and Wolfinger R.D. The analysis of repeated measures with mixed-model adjusted F-tests. Educational and Psychological Measurement 64 (2004) 222-242
29. Krystal J.H., Belger A., D'Souza C., Anand A., Charney D.S., Aghajanian G.K., and Moghaddam B. Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacologyogy 22 (1999) S143-S157
30. Kushner M.G., Kim S.W., Donahue C., Thuras P., Adson D., Kotlyar M., McCabe J., Peterson J., and Foa E.B. D-cycloserine augmented exposure therapy for obsessive compulsive Disorder. Biological Psychiatry 62 (2007) 835-838
31. Lafleur D.L., Pittenger C., Kelmendi B., Gardner T., Wasylink S., Malison R.T., Sanacora G., Krystal J.H., and Coric V. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology 184 (2006) 254-256
32. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., Bovet P., Bush A.I., Conus P., Copolov D., Fornari E., Meuli R., Solida A., Vianin P., Cuénod M., Buclin T., and Do K.Q. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacologyogy 33 (2008) 2187-2199
33. McArdle J.J., and Aber M.S. An introduction to latent growth models for developmental data analysis. In: Little T.D., Schanbel K.U., and Baumert J. (Eds). Modeling Longitudinal and Multi-level data: Practical Issues, Applied Approaches, and Specific Examples (2000), Lawrence Erlbaum, Mahwah, NJ
34. McGrath M.J., Campbell K.M., Parks III C.R., and Burton F.H. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Research 877 (2000) 23-30
35. Moghaddam B., Adams B., Verma A., and Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience 17 (1997) 2921-2927
36. Moghaddam B., and Jackson M.E. Glutamatergic animal models of schizophrenia. Annals of the New York Academy of Sciences 1003 (2003) 131-137
37. Murphy D.L., Pickar D., and Alterman I.S. Methods for the quantitative assessment of depressive and manic behavior. In: Burdock E.L., Sudilovsky A., and Gershon S. (Eds). The Behavior of Psychiatric Patients (1982), Marcel Dekker, New York 355-392
38. Nordstrom E.J., and Burton F.H. A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. Molecular Psychiatry 7 (2002) 617-625
39. Parsons C.G., Danysz W., and Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News & Perspectives 11 (1998) 523-569
40. Pasquini M., and Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30 (2006) 1173-1175
41. Pittenger C., Bloch M., Wegner R., Teitelbaum C., Krystal J.H., and Coric V. Glutamatergic dysfunction in obsessive-compulsive disorder and the potential clinical utility of glutamate-modulating agents. Primary Psychiatry 13 (2006) 65-77
42. Pittenger C., Krystal J.H., and Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 3 3 (2006) 69-81
43. Poyurovsky M., Weizman R., Weizman A., and Koran L. Memantine for treatment-resistant OCD. American Journal of Psychiatry 162 (2005) 2191-2192
44. 3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neuroscience Letters 306 (2001) 81-84
45. Saxena S., Brody A.L., Schwartz J.M., and Baxter L.R. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. British Journal of Psychiatry 173 suppl. 35 (1998) 26-37
46. Sheehan D.V. The Anxiety Disease (1983), Scribner, New York pp. 150-151
47. Stewart S.E., Fagerness J.A., Platko J., Smoller J.W., Scharf J.M., Illmann C., Jenike E., Chabane N., Leboyer M., Delorme R., Jenike M.A., and Pauls D.L. Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. American Journal of Medical Genetics B (Neuropsychiatric Genetics) 144 (2007) 1027-1033
48. Thuile J., Even C., and Guelfi J.-D. Topiramate may induce obsessive-compulsive disorder. Psychiatry and Clinical Neurosciences 60 (2006) 394
49. Van Ameringen M., Mancini C., Patterson B., and Bennett M. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depression and Anxiety 23 (2006) 1-5
50. Wilhelm S., Buhlmann U., Tolin D.F., Meunier S.A., Pearlson G.D., Reese H.E., Cannistraro P., Jenike M.A., and Rauch S.L. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry 165 (2008) 335-341